Literature DB >> 26241020

RAS blockade: Nephroprotection by dual RAS blockade--a welcome back.

Piero Ruggenenti1, Giuseppe Remuzzi1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26241020     DOI： 10.1038/nrneph.2015.132

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Authors:  Jun Cheng; Wen Zhang; Xiaohui Zhang; Fei Han; Xiayu Li; Xuelin He; Qun Li; Jianghua Chen
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

2.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Authors:  Linda F Fried; Nicholas Emanuele; Jane H Zhang; Mary Brophy; Todd A Conner; William Duckworth; David J Leehey; Peter A McCullough; Theresa O'Connor; Paul M Palevsky; Robert F Reilly; Stephen L Seliger; Stuart R Warren; Suzanne Watnick; Peter Peduzzi; Peter Guarino
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

Review 3.  The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

4.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

5.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

6.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

7.  Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.

Authors:  Ruth Campbell; Fabio Sangalli; Elena Perticucci; Claudio Aros; Cecilia Viscarra; Annalisa Perna; Andrea Remuzzi; Federico Bertocchi; Luca Fagiani; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

Review 8.  Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Dimitris Mavridis; Eliano Navarese; Jonathan C Craig; Marcello Tonelli; Georgia Salanti; Natasha Wiebe; Marinella Ruospo; David C Wheeler; Giovanni F M Strippoli
Journal:  Lancet       Date:  2015-05-23       Impact factor: 79.321
  8 in total
  2 in total

1.  Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.

Authors:  Paul M Palevsky; Jane H Zhang; Stephen L Seliger; Nicholas Emanuele; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-27       Impact factor: 8.237

Review 2.  Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.

Authors:  Antonio Mastrangelo; Jessica Serafinelli; Marisa Giani; Giovanni Montini
Journal:  Front Pediatr       Date:  2020-05-12       Impact factor: 3.418
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.